Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




N-acetylcysteine Protects Dopamine-Producing Neurons from Stress Damage and Eases Parkinson's Symptoms

By LabMedica International staff writers
Posted on 27 Jun 2016
A preliminary clinical study demonstrated the effectiveness of n-acetylcysteine (NAC) in promoting survival of neurons and alleviating symptoms in patients with Parkinson's disease (PD).

Previous studies have shown that oxidative stress in the brain may play an important role in the Parkinson's disease process, and that this stress reduces levels of the antioxidant glutathione. More...
NAC acts to reduce oxidative damage to neurons by restoring glutathione levels.

The purpose of the clinical study carried out by investigators from Thomas Jefferson University (Philadelphia, PA, USA) was to explore the effects of NAC using both an in vitro and in vivo approach. To find supportive data for the pilot clinical study, the investigators performed a cell line tissue culture study in which they used a model of PD that employed midbrain dopamine (mDA) neurons generated from human embryonic stem cells (hESCs) to determine whether NAC could protect these mDA neurons from damage resulting from exposure to increasing doses of the PD-like neurotoxin, rotenone.

In the clinical study, patients continued their standard of care and were randomized to receive either daily NAC, alternating between oral and IV administration, or no NAC. Patients were evaluated before and after three months of receiving NAC with DaTscan to measure dopamine transporter (DAT) binding and the Unified Parkinson’s Disease Rating Scale (UPDRS) to measure clinical symptoms.

Results published in the June 16, 2016, online edition of the journal PLOS One revealed that in the cell line study NAC exposure resulted in significantly more mDA neurons surviving after exposure to rotenone compared to no NAC, consistent with the protective effects of NAC previously observed. In the clinical trial the patients receiving NAC had improvements of 4-9% in dopamine transporter binding and about a 13% improvement in their UPDRS score as compared to untreated control patients.

"This study reveals a potentially new avenue for managing Parkinson's patients and shows that n-acetylcysteine may have a unique physiological effect that alters the disease process and enables dopamine neurons to recover some function," said senior author Dr. Daniel Monti, professor of integrative medicine at Thomas Jefferson University.

Related Links:
Thomas Jefferson University



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.